**10. Conclusion**

capable of penetrating the various biological barriers of human body to identify the cancer cells. Thus, nanodrug delivery systems have a leading role to play in nanomedicine in near

> Non small Cell lung cancer

Advanced solid malignancies

Unspecified adult solid tumor

> Rheumatoid arthritis

Liposome <sup>I</sup> Advanced cancer Cisplatin and

Head and neck cancer

Abbreviations: PEG-Polyethylene glycol, TNF-Tumor necrosis factor, NCI-National Cancer Institute, AuNP-Gold nanoparticles

Nanocarriers may lead to a solution to major unsolved medical problems which will aggres‐

**Regulatory aspect:** One of the main areas related to the safety aspects of drug-nanocarrier systems is to encourage academic organizations, industry and regulatory governmental agencies to establish convincing testing procedures on the safety aspects of the nanomaterials.

Liposome II Kaposi's sarcoma

Not stated

**Table 1.** Recent Nanodrug Carriers in Clinical Trials (Source: Clinicaltrials.gov)

LE-DT Liposome II Pancreatic cancer Doxetaxel Insys Therapeutics Inc NCT01186731

Paclitaxel

Docetaxel

II Prostate cancer Paclitaxel OHSU Knight Cancer

Recombinant

doxorubicin

Doxorubicin and bevacizumab

> AP5346 and oxaliplatin

**Delivered Sponsor Clinicaltrials. gov**

Samyang Biopharmaceutical Corp

Samyang Biopharmaceutical Corp

TNF NCI NCT00356980

Institute

factor VIII Bayer NCT00629837

Prednisolone Radboud University NCT00241982

M.D. Anderson Cancer Center

> University of California, San Diego

**Identifier**

NCT01023347

NCT01103791

NCT00459810

NCT00507962

NCT00415298

NCI NCT00923936

**Product name Delivery material Phase Condition Therapeutic**

I

I

Amphilic diblock Copolymer forming micelle

nanoparticles

Drug Polymer Conjugate

Kogenate FS PEG-liposome I Hemophilia A

Liposome II

CYT-6091 AuNP I

future.

Genexol-PM

Paclitaxel poliglumex

Long-circulating liposomal prednisolone disodium phosphate

> Cisplatin and Liposomal Doxorubicin

Liposomal doxorubicin and bevacizumab

AP5346 Drug polymer

sively enhance quality of life.

conjugate

Docetaxel-PNP Polymeric

538 Application of Nanotechnology in Drug Delivery

Last few years several new technologies have been developed for the treatment of various diseases. The use of nanotechnology in developing nanocarriers for drug delivery is bringing lots of hope and enthusiasm in the field of drug delivery research. Nanoscale drug delivery devices present some advantages which show higher intracellular uptake than the other conventional form of drug delivery systems. Nanocarriers can be conjugated with a ligand such as antibody to favor a targeted therapeutic approach. The empty virus capsids are also being tried to use for delivering drugs as a new therapeutic strategy. Thus, nanoscale size drug delivery systems may revolutionize the entire drug therapy strategy and bring it to a new height in near future. However, toxicity concerns of the nanosize formulations should not be ignored. Full proof methods should be established to evaluate both the short-term and longterm toxicity analysis of the nanosize drug delivery systems.

### **Author details**

Biswajit Mukherjee\* , Niladri Shekhar Dey, Ruma Maji, Priyanka Bhowmik, Pranab Jyoti Das and Paramita Paul

\*Address all correspondence to: biswajit55@yahoo.com

Department of Pharmaceutical Technology, Jadavpur University, Kolkata, India

#### **References**


Parliament, the council and the European and Economic Social Committee on the Second Regulatory Review on Nanomaterials. SWD 2012; 288 Final.

[16] Wei XL, Mo ZH, Li B, Wei JM. Disruption of Hep G2 cell adhesion by gold nanopar‐ ticle and paclitaxel disclosed by *in situ* QCM measurement. Colloids Surf B Biointer‐

Current Status and Future Scope for Nanomaterials in Drug Delivery

http://dx.doi.org/10.5772/58450

541

[17] Yousefi A, Esmaeili F, Rahimian S, Atyabi F, Dinarvand R. Preparation and *in vitro* evaluation of a pegylated nano-liposomal formulation containing docetaxel. Sci

[18] Patel S, Bhirde AA, Rusling JF, Chen X, Gutkind JS, Patel V. Nano delivers big: de‐ signing molecular missiles for cancer therapeutics. Pharmaceutics. 2011; 3(1): 34-52.

[19] Patel RP, Patel H, Baria AH. Formulation and evaluation of liposomes of ketokona‐

[20] Kumar A, Badde S, Kamble R, Pokharkar VB. Development and characterization of liposomal drug delivery system for nimesulide. Int J Pharm Pharm Sci. 2010; 2(4):

[21] Arab Tehrany E, Kahn CJ, Baravian C, Maherani B, Belhaj N, Wang X, Linder M. Elaboration and characterization of nanoliposome made of soya, rapeseed and sal‐ mon lecithins: application to cell culture. Colloids Surf B Biointerfaces. 2012; 95:

[22] Kumar KPS, Bhowmik D, Deb L. Recent trends in liposomes used as novel drug de‐

[23] Dadashzadeh S, Vali AM, Rezaie M. The effect of PEG coating on *in vitro* cytotoxicity and *in vivo* disposition of topotecan loaded liposomes in rats. Pharmaceutical Nano‐

[24] Dhanikula RS, Hammady T, Hildgen P. On the mechanism and dynamics of uptake and permeation of polyether copolyester dendrimers across an *in vitro* blood-brain

[25] Albertazzi L, Gherardini L, Brondi M, Sulis Sato S, Bifone A, Pizzorusso T, Ratto GM, Bardi G. *In vivo* distribution and toxicity of PAMAM dendrimers in the central nerv‐ ous system depend on their surface chemistry. Mol Pharmacol. 2013; 10(1): 249-260.

[26] Kannan S, Dai H, Navath RS, Balakrishnan B, Jyoti A, Janisse J, Romero R, Kannan RM. Dendrimer-based postnatal therapy for neuroinflammation and cerebral palsy

[27] Klajnert B, Bryszewska M. Dendrimers: properties and applications. Acta Bioch Pol.

[28] Huang RQ, Qu YH, Ke WL, Zhu JH, Pei YY, Jiang C. Efficient gene delivery targeted to the brain using a transferrin-conjugated polyethylene glycol-modified polyamido‐ amine dendrimer. Drug Delivery Systems: Advanced Technologies Potentially Ap‐

faces. 2007; 59: 100-104.

Pharm. 2009; 77: 453-464.

87-89.

75-81.

zole. Int J Drug Deliv Technol. 2009; 1(1): 16-23.

livery system. J Pharma Innovation. 2012; 1(1): 26-34.

barrier model. J Pharm Sci. 2009; 98(10): 3748-3760.

in a rabbit model. Sci Transl Med. 2012; 4(130): 130ra46.

plicable in Personalised Treatment. 2007; 21(4): 1117-1125.

technology. 2008; 353: 251-259.

2001; 48(1): 199-208.


[16] Wei XL, Mo ZH, Li B, Wei JM. Disruption of Hep G2 cell adhesion by gold nanopar‐ ticle and paclitaxel disclosed by *in situ* QCM measurement. Colloids Surf B Biointer‐ faces. 2007; 59: 100-104.

Parliament, the council and the European and Economic Social Committee on the

[3] Svenson S, Prud'homme RK. Multifunctional nanoparticles for drug delivery appli‐ cations. The nanotech revolution in drug delivery. Cientifica Ltd. 2007; 978-1-4614-

[4] Hadjipanayis CG, Machaidze R, Kaluzova M, Wang L, Schuette AJ, Chen H, Wu X, Mao H. EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic reso‐ nance imaging- guided convection-enhanced delivery and targeted therapy of glio‐

[5] Jong WHD, Borm PJA. Drug delivery and nanoparticle applications and hazards. Int

[6] Sahoo SK, Parveen S, Panda JJ. The present and future of nanotechnology in human

[7] Webster DM, Sundaram P, Byrne ME. Injectable nanomaterials for drug delivery: carriers, targeting moieties, and therapeutics. Eur J Pharm Biopham. 2013; 84(1): 1-20.

[8] Chakroborty G, Seth N, Sharma V. Nanoparticles and nanotechnology: clinical, toxi‐ cological, social, regulatory and other aspects of nanotechnology. JDDT. 2013; 3(4):

[9] Couvreur P. Nanoparticles in drug delivery: past, present and future. Adv Drug De‐

[10] Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery

[11] Praetorius NP, Mandal TK. Engineered nanoparticles in cancer therapy. Recent Pat

[12] Pardeike J, Hommoss A, Müller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and

[13] Ogawara KI, Un K, Tanaka K, Higaki K, Kimura T. *In vivo* anti-tumor mal doxorubi‐ cin (DOX) in Dox-resistant tumor-bearing mice: involvement of cytotxic effect on

[14] Chan JM, Zhang L, Yuet KP, Liao G, Rhee JW, Langer R, Farokhzad OC. PLGA-leci‐ thin-PEG core-shell nanoparticles for controlled drug delivery. Biomaterials. 2009;

[15] Huang X , Jain PK, El-Sayed IH, El-Sayed MA. Gold nanoparticles: interesting optical properties and recent applications in cancer diagnostics and therapy. Nanomedicine.

pharmaceutical dermal products. Int J Pharm. 2009; 366(1-2): 170-184.

vascular endothelial cells. J Cont Rel. 2009; 133(1): 4-10.

Second Regulatory Review on Nanomaterials. SWD 2012; 288 Final.

blastoma. Cancer Res. 2010; 70(15): 6303- 6312.

healthcare. Nanomed Nanotech Biol Med. 2007; 3(1): 20-31.

to cells and tissue. Adv Drug Delivery Rev. 2003; 55(3):329-347.

J Nanomedicine. 2008; 3(2): 133- 149.

livery Rev. 2013; 65(1): 21-23.

Drug Deliv and Formul. 2007; 1(1): 37-51.

2304-1.

540 Application of Nanotechnology in Drug Delivery

138-141.

30(8): 1627-1634.

2007; 2: 681-693.


[29] Kherlopian AR, Song T, Duan Q, Neimark MA, Po MJ, Gohagan JK, Laine AF. A re‐ view of imaging techniques for systems biology. BMC Syst Biol. 2008; 2: 74.

[45] Gabathuler R. Approaches to transport therapeutic drugs across the blood- brain bar‐

Current Status and Future Scope for Nanomaterials in Drug Delivery

http://dx.doi.org/10.5772/58450

543

[46] Kesavan K, Balasubramaniam J, Kant S, Singh PN, Pandit JK. Newer approaches for optimal bioavailability of ocularly delivered drugs: review. Curr Drug Deliv. 2011;

[47] Yasukawa T. Drug delivery systems for vitreoretinal diseases. Prog Retin Eye Res.

[48] Behar-Cohen F. Drug delivery to target the posterior segment of the eye. Med Sci

[49] Gulsen D, Chauhan A. Ophthalmic drug delivery through contact lenses. Invest

[50] Gulsen D, Chauhan A. Dispersion of microemulsion drops in HEMA hydrogel: a po‐ tential ophthalmic drug delivery vehicle. Int J Pharm. 2005; 292(1-2): 95-117.

[51] Amrite AC, Edelhauser HF, Singh SR, Kompella UB. Effect of circulation on the and ocular tissue distribution of 20 nm nanoparticles after periocular administration. Mol

[52] Kim JH, Kim JH, Kim KW, Kim MH, Yu YS. Intravenously administered gold nano‐ particles passing through the blood retinal barrier depending on the particle size,

[53] Koo H, Moon H, Han H, Na JH, Huh MS, Park JH, Kwon IC, Kim K, Kim H. The movement of self- assembled amphiphilic polymeric nanoparticles in the vitreous

[54] Peeters L, Sanders NN, Braeckmans K, Boussery K, Van de Voorde J, De Smedt SC, Demeester J. Vitreous: a barrier to nonviral ocular gene therapy. Invest Ophthalmol

[55] Kim H, Robinson SB, Csaky KG. Investigating the movement of intravitreal human serum albumin nanoparticles in the vitreous and retina. Pharm Res. 2009; 26(2):

[56] Surendiran A, Sandhiya S, Pradhan SC, Adithan C. Novel applications of nanotech‐

[57] Malam Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: nanosized vehi‐ cles for drug delivery in cancer. Trends Pharmacol Sci. 2009; 30(11): 592-599.

[58] Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparti‐ cle systems in cancer therapeutics. Adv Drug Delivery Rev. 2008; 60: 1615-1626.

[59] Ruoslahti E, Bhatia SN, Sailor MJ. Targeting of drugs and nanoparticles to tumors. J

nology in medicine. Indian J Med Res. 2009; 130: 689-701.

and retina after intravitreal injection. Biomaterials. 2012; 33(12): 3485-3493.

and induce no retinal toxicity. Nanotechnology. 2009; 20(50): 505101.

rier to treat brain diseases. Neuro biology of Disease. 2010; 37(1): 48-57.

8(2): 172-193.

2004; 23(3): 253-281.

Vis. 2008; 14: 150-160.

Vis Sci. 2005; 46(10): 3553-3561.

Cell Biol. 2010; 188 (6): 759-768.

329-337.

(Paris). 2004; 20(6-7): 701-706.

Ophthalmol Vis Sci. 2004; 45(7): 2342-2347.


[45] Gabathuler R. Approaches to transport therapeutic drugs across the blood- brain bar‐ rier to treat brain diseases. Neuro biology of Disease. 2010; 37(1): 48-57.

[29] Kherlopian AR, Song T, Duan Q, Neimark MA, Po MJ, Gohagan JK, Laine AF. A re‐ view of imaging techniques for systems biology. BMC Syst Biol. 2008; 2: 74.

[30] Lowery AR, Gobin AM, Day ES, Halas NJ, West JL. Immunonano shells for targeted

[31] Hirsch LR, Stafford RJ, Bankson JA, Sershen SR, Rivera B, Price RE. Nanosell-mediat‐ ed near-infrared thermal therapy of tumors under magnetic resonance guidance.

[32] Reilly RM. Carbon nanotubes: potential benefits and risks of nanotechnology in nu‐

[33] Prato M, Kostarelos K, Bianco A. Functionalized carbon nanotubes in drug design

[34] Mc Devitt MR, Chattopadhyay D, Kappel BJ, Jaggi JS, Schiffman SR, Antczak C, Njardarson JT, Brentjens R, Scheinberg DA. Tumor targeting with antibody function‐

[35] Freitas RA. Current status of nanomedicine and medical nanorobotics. J Comput

[36] Yadav A, Ghune M, Jain DK. Nanomedicine based drug delivery system. JAPER.

[37] Gangrade SM. Nanocrystals-a way for carrier free drug delivery. Pharma Buzz. 2011;

[38] Gao X, Dave SR. Quantum dots for cancer molecular imaging. Adv Exp Med Boil.

[39] Mulder WJM, Koole R, Brandwijk RJ, Storm G, Chin PTK, Strijkers GJ, Donega CM, Nicolay K, Griffioen AW. Quantum dots with a paramagnetic coating as a bimodal

[40] Jain S, Shukla K, Jain V, Saraf S. Nanoparticles: emerging carriers for delivery of bio‐

[41] Amiot CL, Xu S, Liang S, Pan L, Zhao JX. Near-infrared fluorescent materials for

[42] Petty MA, Lo EH. Junctional complexes of the blood brain barrier: permeability

[43] Rabanel JM, Aoun V, Elkin I, Mokhtar M, Hildgen P. Drug loaded nanocarriers: pas‐ sive targeting and crossing of biological barriers. Curr Med Chem. 2012; 19(19):

[44] Youns M, Hoheisel JD, Efferth T. Therapeutic and diagnostic applications of nano‐

alized, radiolabelled carbon nanotubes. J Nucl Med. 2007; 48: 1180-1189.

photothermal ablation of tumor cells. Int J Nanomed. 2006; 1(2): 149-154.

Prof Natl Acad Sci USA. 2003; 100: 13549-13554.

and discovery. Acc Chem Res. 2008; 41(1): 60-68.

molecular imaging probe. Nano letter. 2006; 6: 87-90.

sensing of biological targets. Sensors. 2008; 8(5): 3082-3105.

changes in neuroinflammation. Prog Neurobiol. 2002; 68(5): 311-323.

active agents. Pharma Times. 2007; 39: 30-35.

particles. Curr Drug Targets. 2011; 12(3): 357-365.

Theor Nanosci. 2005; 2: 1-25.

2011; 1(4): 201- 213.

542 Application of Nanotechnology in Drug Delivery

2007; 620: 57-73.

6: 26-31.

3070-3102.

clear nuclear medicine. J Nucl Med. 2007; 48(7): 1039-1042.


[60] Praetorius NP, Mandal TK. Engineered nanoparticles in cancer therapy. Recent Pat

[61] Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nature Nanotech. 2007; 2: 751-760.

[62] Lammers T, Hennink WE, Storm G. Tumour-targeted nanomedicines: principles and

[64] Alex SM, Sharma CP. Nanomedicine for gene therapy. Drug Deliv Transl Res. 2013;

[65] Pathak A, Vyas SP, Gupta KC. Nano-vectors for efficient liver specific gene transfer.

[66] Bunuales M, Duzgunes N, Zalba S, Garrido MJ, Ilarduya CT. Efficient gene delivery

[67] Boettger M, Zaitsev S, Cartier R, Haberland A, Sukhorukov G, Moehwald H, Zas‐

[68] Niu L, Xu YC, Dai Z, Tang HQ. Gene therapy for type 1 diabetes mellitus in rats by gastrointestinal administration of chitosan nanoparticles containing human insulin

[69] Caruso M, Belloni L, Sthandier O, Amati P, Garcia MI. Alpha4beta1 integrin acts as a cell receptor for murine polyomavirus at the level. J Virol. 2003; 77: 3913- 3921. [70] Young M, Willits D, Uchida M, Douglas T. Plant viruses as biotemplates for materi‐ als and their use in nanotechnology. Annu Rev Phytopathol. 2008; 46: 361-384. [71] Gleiter S, Lilie H. Cell-type specific targeting and gene expression using a polyoma

[72] Wang Q, Chan TR, Hilgraf R, Fokin VV, Sharpless KB, Finn MG. Bioconjugation by copper (I)-catalyzed azide-alkyne [3+2] cycloaddition. J Am Chem Soc. 2003; 125(11):

by EGF lipoplexes *in vitro* and *in vivo*. Nanomedicine. 2011; 6(1): 89-98.

[63] Davis PB, Cooper MJ. Vectors for airway gene delivery. AAPS J. 2007; 9: E11-E17.

Drug Deliv Formul. 2007; 1(1): 37-51.

Int J Nanomed. 2008; 3: 31-49.

3: 437-445.

544 Application of Nanotechnology in Drug Delivery

3192 - 3193.

practice. British Journal of Cancer. 2008; 99: 392-397.

trow H, Schneider M. WO03087384A1 (2003).

gene. World J Gastroenterol. 2008; 14: 4209-4215.

VP1 virus-like particles. Biol Chem. 2003; 384(2): 247- 255.
